Insider · CIK 0001055951
Orbimed Advisors LLC
directorowner
Files at PASG (Passage BIO, Inc.), ADRX (ADARx Pharmaceuticals, Inc.), IRON (Disc Medicine, Inc.), Lomond Therapeutics Holdings, Inc., UPB (Upstream Bio, Inc.), ETRA (Electra Therapeutics, Inc.). First filing Oct 17, 2024, latest Sep 30, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 1
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
3 / 6
$50M bought, $20M sold
Where the trades landed
Last year at the 3 companies this insider has traded most, with each buy and sell on the bar it happened.
IRON: Disc Medicine, Inc.
IRONOct 9, 2026 · close 62.06
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
PASG: Passage BIO, Inc.
PASGOct 9, 2026 · close 3.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
ADRX: ADARx Pharmaceuticals, Inc.
ADRXOct 9, 2026 · close 17.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | ADARx Pharmaceuticals, Inc. | $16M 950,000 shares | +7% | - | |
| 54Moderate | Electra Therapeutics, Inc. | $20M 1,333,333 shares | +28% | - | |
| 37Weak | Disc Medicine, Inc. | $310k 5,738 shares | -1% | - | |
| 53Moderate | Disc Medicine, Inc. | $2.8M 52,429 shares | -10% | - | |
| 68Notable | Disc Medicine, Inc. | $17M 312,384 shares | -51% | - | |
| 23Weak | PASGsell Passage BIO, Inc. | $138k 230,321 shares | -3% | - | |
| 19Weak | PASGsell Passage BIO, Inc. | $52k 62,276 shares | -1% | - | |
| 20Weak | PASGsell Passage BIO, Inc. | $77k 97,103 shares | -1% | - | |
| 65Notable | Upstream Bio, Inc. | $14M 825,000 shares | +85% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +300,249 | $17.00 | $5.1M | 14,325,529 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +588,235 | $17.00 | $10.0M | 588,235 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 11 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +2,002,310 | - | - | 2,002,310 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +1,087,934 | - | - | 3,090,244 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +1,703,314 | - | - | 4,793,558 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +333,333 | $15.00 | $5.0M | 5,126,891 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +758,279 | - | - | 758,279 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,758,279 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnotes | -2,002,310 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnotes | -1,087,934 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -1,703,314 | $0.00 | $0 | 0 | 18 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -758,279 | $0.00 | $0 | 0 | 18 d ago |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,956 | $54.11 | $106k | 482,308 | Mar 26, 2025 |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,026 | $54.11 | $164k | 746,171 | Mar 26, 2025 |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -756 | $54.11 | $41k | 186,541 | Mar 26, 2025 |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -13,517 | $54.02 | $730k | 488,617 | Mar 21, 2025 |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -20,911 | $54.02 | $1.1M | 755,933 | Mar 21, 2025 |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -5,228 | $54.02 | $282k | 188,981 | Mar 21, 2025 |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -941 | $54.01 | $51k | 487,676 | Mar 21, 2025 |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,457 | $54.01 | $79k | 754,476 | Mar 21, 2025 |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -364 | $54.01 | $20k | 188,617 | Mar 21, 2025 |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,412 | $54.00 | $184k | 484,264 | Mar 21, 2025 |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -5,279 | $54.00 | $285k | 749,197 | Mar 21, 2025 |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,320 | $54.00 | $71k | 187,297 | Mar 21, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -68,766 | $54.29 | $3.7M | 539,845 | Mar 12, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -106,384 | $54.29 | $5.8M | 835,185 | Mar 12, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -26,596 | $54.29 | $1.4M | 208,795 | Mar 12, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -136 | $55.01 | $7,481 | 539,709 | Mar 12, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -211 | $55.01 | $12k | 834,974 | Mar 12, 2025 |
| Mar 10, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -53 | $55.01 | $2,916 | 208,742 | Mar 12, 2025 |
| Mar 11, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -9,222 | $54.01 | $498k | 530,487 | Mar 12, 2025 |
| Mar 11, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -14,267 | $54.01 | $771k | 820,707 | Mar 12, 2025 |
| Mar 11, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,567 | $54.01 | $193k | 205,175 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -603 | $55.05 | $33k | 529,884 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -933 | $55.05 | $51k | 819,774 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -233 | $55.05 | $13k | 204,942 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -27,750 | $54.44 | $1.5M | 502,134 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -42,930 | $54.44 | $2.3M | 776,844 | Mar 12, 2025 |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -10,733 | $54.44 | $584k | 194,209 | Mar 12, 2025 |
| Dec 20, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -230,321 | $0.60 | $138k | 7,404,869 | Dec 26, 2024 |
| Dec 9, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -54,181 | $0.84 | $46k | 7,643,285 | Dec 11, 2024 |
| Dec 10, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -8,015 | $0.80 | $6,412 | 7,635,270 | Dec 11, 2024 |
| Dec 11, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -80 | $0.80 | $64 | 7,635,190 | Dec 11, 2024 |
| Dec 4, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -76,200 | $0.79 | $60k | 7,718,369 | Dec 6, 2024 |
| Dec 6, 2024 | PASG Passage BIO, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -20,903 | $0.82 | $17k | 7,697,466 | Dec 6, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +323,916 | $3.20 | $1.0M | 323,916 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +215,146 | $3.20 | $688k | 539,062 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +389,078 | $3.60 | $1.4M | 928,140 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +230,753 | $3.60 | $831k | 1,158,893 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +74,613 | $3.60 | $269k | 1,233,506 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +808,894 | $4.00 | $3.2M | 2,042,400 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +479,736 | $4.00 | $1.9M | 2,522,136 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +155,120 | $4.00 | $620k | 2,677,256 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -323,916 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -215,146 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -389,078 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -230,753 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -74,613 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Common Stockindirect: See Footnote | +721,956 | - | - | 973,716 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +165,000 | $17.00 | $2.8M | 1,138,716 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Common Stockindirect: See Footnote | +2,887,833 | - | - | 3,894,873 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +660,000 | $17.00 | $11M | 4,554,873 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -524,500 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -2,098,000 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -197,456 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -789,833 | - | - | 0 | Oct 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.